Large cap biotechnology companies are flush with cash, and they’re on the prowl for takeover targets, a scenario that could bode well for the ALPS Medical Breakthroughs ETF (SBIO). SBIO focuses on small- and mid-cap companies that have one or more drugs in either Phase II or Phase III trials....